Physiogenex and its subsidiary company Cardiomedex will be presenting their original preclinical models during the Moderated ePosters session entitled “Pathomechanisms of heart failure with preserved ejection fraction” on August the 28th, 2022 2:15pm-3pm at the ESC 2022 in Barcelona, Spain.

2 moderated e-poster will be presented by Dr. François Briand, our Director of Research and Development at Physiogenex, to demonstrate the relevance of the obese NASH hamster model and the LundMetS rat for the study of HFpEF:

•Enhancing NO pathway improves diastolic function in a hamster model of heart failure with preserved ejection fraction associated with nonalcoholic steatohepatitis

•A promising rat model of heart failure with preserved ejection fraction associated to multiple comorbidities

Contact us if you wish to set-up an appointment with Dr. Briand during the ESC 2022 and/or discuss your drug development projects with us.

About us

 Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications.

We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis), cardiovascular and renal complications.